- Asep Medical ( OTCQB:SEPSF ) said on Monday that on Sept. 29, 2022 it signed a joint venture term sheet with a Chinese medical diagnostic company Sansure Biotech.
- The term sheet is aimed at a joint venture in preparation for the research, development, sublicensing and commercialization of SepsetER, Asep first-generation sepsis diagnostic kit for use in the Chinese market, the companies added.
- The companies noted that they will continue to negotiate the specific collaboration terms with the aim of signing a definitive agreement in the coming months.
- Asep said that its early sepsis diagnostic kit is developed using artificial intelligence.
- "Sansure is one of the largest companies selling PCR-based diagnostic assays, which is the technology utilized in our Sepset test," said Asep's Founder, Chairman and CEO Robert Hancock.
For further details see:
Asep plans to form joint venture to develop, sell sepsis diagnostic test in China